

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 14D-9**

SOLICITATION/RECOMMENDATION STATEMENT  
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

---

**Spark Therapeutics, Inc.**  
(Name of Subject Company)

---

**Spark Therapeutics, Inc.**  
(Name of Persons Filing Statement)

---

Common Stock, par value \$0.001 per share  
(Title of Class of Securities)

84652J103  
(CUSIP Number of Class of Securities)

Jeffrey D. Marrazzo  
Chief Executive Officer  
3737 Market Street  
Philadelphia, PA 19104  
(Name, Address and Telephone Number, including area code, of Agent For Service)

*With copies to:*

Stuart M. Cable, Esq.  
Lisa R. Haddad, Esq.  
Blake Liggio, Esq.  
Goodwin Procter LLP  
100 Northern Avenue  
Boston, MA 02210  
(617) 570-1000  
(Name, address, and telephone numbers of person authorized to receive notices and communications  
on behalf of the persons filing statement)

---

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

The information set forth under Items 1.01, 5.03, 7.01 and 9.01 of the Current Report on Form 8-K filed by Spark Therapeutics, Inc. on February 25, 2019 (including all exhibits attached thereto) is incorporated herein by reference.

---

---